Abstracts tagged "Surveys"

Abstract Number: 2170 • ACR Convergence 2025
I Know It When I See It! Improving Visual Diagnosis Education in Rheumatology Fellowship Training
Amarjyot Randhawa¹, Laura Nichols², Jason Kolfenbach³, Meredith Morcos² and Steven Taylor³, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado, Aurora, CO, ³University of Colorado, Denver, CO
Background/Purpose: Visual diagnosis, based on both physical exam and imaging studies, is of great importance in clinical practice and for board exam purposes in rheumatology.…
Abstract Number: 1047 • ACR Convergence 2025
Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Ellen Ann Sockman¹, Jon Golenbiewski¹ and Rachel Wolfe², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Wake Forest University School of Medicine, Winston-Salem
Background/Purpose: Giant Cell Arteritis (GCA) is a medical emergency that can lead to irreversible vision loss without prompt recognition and treatment. Primary care providers (PCPs)…
Abstract Number: 0144 • ACR Convergence 2025
Duration of Anticoagulation in Antiphospholipid Antibody-positive Patients: Results from an AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Survey
Zeynep Belce Erton¹, Joann Vega², Hannah Cohen³ and Doruk Erkan², ¹Hospital for Special Surgery, Brooklyn, NY, ²hospital for special surgery, New York, NY, ³University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: APS ACTION is a multidisciplinary, international research network focused on developing collaborative studies to improve antiphospholipid syndrome (APS) diagnosis and management. There is limited…
Abstract Number: 2166 • ACR Convergence 2025
Clinical Disease Activity Index (CDAI) for Rheumatoid Arthritis: A Clinical Educational Workshop
Ahmed Rubia¹, Nancy Olsen², Saurav Suman³, Sharon Banks⁴, Shirley Albano Aluquin¹, Kristie Pepper⁵ and Rayford June⁶, ¹Penn State Milton S. Hershey Medical Cen, Hershey, PA, ²Penn State University/Milton S Hershey, Hershey, PA, ³Penn State Milton S. Hershey Medical Cen, Harrisburg, PA, ⁴Penn State Milton S. Hershey Medical Center, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Cen, Lebanon, PA, ⁶Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA
Background/Purpose: The Clinical Disease Activity Index (CDAI) is one of six assessment measures for rheumatoid arthritis (RA) recommended for management of RA in clinical practice.…
Abstract Number: 1046 • ACR Convergence 2025
Cannabis Knowledge, Attitudes, and Practices Among Rheumatology Providers: Implications for Clinical Care and Education
Joanna Zeiger¹, Patti Katz², Mary-Ann Fitzcharles³, Stuart Kassan⁴, Teresa Simon⁵ and Kaleb Michaud⁶, ¹Canna Research Foundation, Boulder, CO, ²UCSF, San Rafael, CA, ³McGill University, Montreal-West, Canada, ⁴National Jewish Health, Denver, CO, ⁵Physicians Research Center, LLC, Toms River, NJ, ⁶University of Nebraska Medical Center, Omaha, NE
Background/Purpose: As medical cannabis becomes increasingly integrated into clinical care, healthcare providers—particularly those managing chronic rheumatologic conditions—must navigate wide-ranging levels of knowledge, attitudes, and prescribing…
Abstract Number: 2138 • ACR Convergence 2025
Factors driving therapeutic decision-making in Still’s Disease: When to Start and When to Stop? Data from the METAPHOR Project Worldwide Survey
Francesco Baldo¹, Greta Rogani², Claudia Bracaglia³, Dirk Foell⁴, Marco Gattorno⁵, Marija Jelusic⁶, Jordi Anton⁷, Paul Brogan⁸, Scott Canna⁹, Randy Cron¹⁰, Fabrizio De Benedetti¹¹, Alexei Grom¹², Merav Heshin Bekenstein¹³, AnnaCarin Horne¹⁴, Raju Khubchandani¹⁵, Mao Mizuta¹⁶, Seza Özen¹⁷, Pierre Quartier Dit Maire¹⁸, Angelo Ravelli¹⁹, Masaki Shimizu²⁰, Grant Schulert¹², Christiaan Scott²¹, Rashmi Sinha²², Nicolino Ruperto²³, Joost Swart²⁴, Bruno Fautrel²⁵, Sebastiaan Vastert² and Francesca Minoia²⁶, ¹ASST-Pini-CTO, Milano, Milan, Italy, ²University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, ³IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, ⁴University Hospital Muenster, Muenster, Germany, ⁵IRCCS G. Gaslini, Genova, Genoa, Italy, ⁶University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ⁷Hospital Sant Joan de Düu. Universitat de Barcelona, Esplugues de Llobregat (Barcelona), Spain, ⁸UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁹Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Bambino Gesu Children's Hospital, Rome, Rome, Italy, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ¹⁴Karolinska University Hospital, Sollentuna, Sweden, ¹⁵SRCC Childrens Hospital Mumbai, Mumbai, India, ¹⁶Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan, Kobe, Japan, ¹⁷Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁸Necker hospital, Paris Cedex ¹⁵, France, ¹⁹IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ²⁰Tokyo Medical and Dental University, Bunkyo-ku, Kanazawa, Japan, ²¹Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ²²Systemic JIA Foundation, Cincinnati, OH, ²³Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ²⁴Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ²⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁶Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite continuous improvement in care and the recent update of international recommendations, relevant discrepancies in the diagnostic and treatment approach to Still’s disease (SD)…
Abstract Number: 1043 • ACR Convergence 2025
The Care Pathway and Treatment Patterns in Patients with Uncontrolled Gout: A Real-World Survey of Physicians In The United States
Gordon Lam¹, Menaka Bhor², James Hawthorne², Arinola Dada³, Molly Edwards⁴, Emily Goddard⁴ and John Albert⁵, ¹Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, ²Sobi Inc, Waltham, MA, ³Overlake Arthritis and Osteoporosis Center, Bellevue, WA, ⁴Adelphi Real World, Bollington, United Kingdom, ⁵Rheumatic Disease Center, Glendale, WI
Background/Purpose: Uncontrolled gout (UG) is a chronic, progressive, and systemic disease characterized by serum uric acid (sUA) >6 mg/dl and clinical manifestations such as tophi,…
Abstract Number: 2137 • ACR Convergence 2025
Therapeutic Strategies in Newly Diagnosed Still’s Disease: Real-Life Clinicians’ Choices from the METAPHOR Project Worldwide Survey
Francesco Baldo¹, Greta Rogani², Claudia Bracaglia³, Dirk Foell⁴, Marco Gattorno⁵, Jordi anton⁶, Paul Brogan⁷, Scott Canna⁸, randy Cron⁹, Alexiei GROM¹⁰, Merav Heshin Bekenstein¹¹, Raju Khubchandani¹², Seza Özen¹³, Pierre Quartier¹⁴, Angelo Ravelli¹⁵, Grant Schulert¹⁶, Mao Mizuta¹⁷, Joost Swart¹⁸, Rashmi Sinha¹⁹, AnnaCarin Horne²⁰, Fabrizio De Benedetti²¹, Christiaan Scott²², Marija Jelusic²³, Masaki Shimizu²⁴, Bruno Fautrel²⁵, Nicolino Ruperto²⁶, Sebastiaan Vastert² and Francesca Minoia²⁷, ¹ASST-Pini-CTO, Milano, Milan, Italy, ²University Medical Center Utrecht, Utrecht, Utrecht, Netherlands, ³IRCCS Ospedale Pediatrico Bambino Gesu', Rome, Rome, Italy, ⁴Universisty Hospital of Muenster, Muenster, ⁵IRCCS G. Gaslini, Genova, Genoa, Italy, ⁶Hospital Sant Joan de Düu. Universitat de Barcelona, Barcelona, Spain, ⁷UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁸Children's Hospital of Philadelphia, Philadelphia, PA, ⁹University of Alabama at Birmingham, Birmingham, AL, ¹⁰Cincinnati Children’s Hospital Medical Center, Division of Rheumatology, Cincinnati, OH, ¹¹Tel Aviv Medical Center Israel, Binyamina, Tel Aviv, Israel, ¹²Jaslok Hospital and Research Center, Mumbai, India, ¹³Hacettepe University Medical Faculty, Ankara, Turkey, ¹⁴Hôpital Necker-Enfants Malades, Paris, France, ¹⁵IRCCS Istituto Giannina Gaslini, Genoa, Italy, Genoa, Genoa, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁷Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan, Kobe, Japan, ¹⁸Wilhelmina Children's Hospital / UMC Utrecht, Utrecht, Utrecht, Netherlands, ¹⁹Systemic JIA Foundation, Cincinnati, OH, ²⁰Karolinska University Hospital, Sollentuna, Sweden, ²¹Bambino Gesu Children's Hospital, Rome, Rome, Italy, ²²Childrens Hospital of Eastern Ontario (CHEO), Ottawa, ON, Canada, ²³University of Zagreb School of Medicine, University Hospital Centre Zagreb, Zagreb, Zagreb, Croatia, ²⁴Tokyo Medical and Dental University, Bunkyo-ku, Kanazawa, Japan, ²⁵Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ²⁶Université Milano Bicocca and Fondazione IRCSS S. Gerardo dei Tintori, Monza, Monza and Brianza, Italy, ²⁷Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Milan, Italy
Background/Purpose: Despite continuous advances in care and the recent publication of updated international recommendations, relevant discrepancies in the management of Still’s disease (SD) may still…
Abstract Number: 1021 • ACR Convergence 2025
Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Kristin Wipfler¹ and Kaleb Michaud², ¹FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Cannabis use has increased substantially in the general population over the past decade, driven by changing legal landscapes and expanding public interest in its…
Abstract Number: 2067 • ACR Convergence 2025
Patterns of Comorbidity in Idiopathic Inflammatory Myopathies: A Cross-sectional Analysis of Disease Burden and Risk Factors
Ilke Coskun Benlidayi¹, Meghna Lama², Oladipo Kunle Afolayan², Meera Shah³, Manali Sarkar⁴, Tamar Rubinstein⁵, Aleksandra Opinc-Rosiak⁶, Rada Miskovic⁷, Marcin Milchert⁸, Dimitri Luz Felipe da Silva⁹, Samuel Katsuyuki Shinjo¹⁰, Elena Nikiphorou¹¹, Ioannis Parodis¹², Vincenzo Venerito¹³, Vikas Agarwal¹⁴ and Latika Gupta¹⁵, ¹Cukurova University, Adana, Turkey, ²The University of Texas Health Science Centre at Houston School of Public Health: Houston, Texas, Houston, ³Indraprastha Apollo Hospital, New Delhi, Mumbai, Maharashtra, India, ⁴Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India., Mumbai, Maharashtra, India, ⁵Albert Einstein College of Medicine, White Plains, NY, ⁶Medical University of Lodz, Zeromskiego ¹¹³, ⁹⁰-⁵⁴⁹ Lodz, Poland., Lodz, Poland, ⁷University of Belgrade; Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Belgrade, Serbia, ⁸Pomeranian Medical University in Szczecin, Szczecin, Poland, ⁹University Santo Amaro, São Paulo, Brazil, Sao Paulo, Brazil, ¹⁰Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ¹¹King's College London, London, United Kingdom, ¹²Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology, Stockholm, Sweden, ¹³Univeristy of Bari "Aldo Moro", Italy, Bari, Bari, Italy, ¹⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India, ¹⁵School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham; Royal Wolverhampton NHS Trust; Centre for Musculoskeletal Research, School of Biological Sciences, The University of Manchester, Manchester; Francis Crick Institute, London, Birmingham, UK, United Kingdom
Background/Purpose: Comorbidities contribute to the disease burden in idiopathic inflammatory myopathies (IIMs). Understanding their distribution and predictors across IIM subtypes can guide tailored strategies. This…
Abstract Number: 0685 • ACR Convergence 2025
Targeting Refractory Reflux in Systemic Sclerosis: Early Outcomes following a Novel Intervention
Areeka Memon¹, Monique Hinchcliff² and Amir Masoud³, ¹Yale New Haven Health, New Haven, CT, ²Yale School of Medicine, Westport, CT, ³Hartford Healthcare, hartford
Background/Purpose: Gastrointestinal tract (GIT) symptoms impact up to 90% of individuals with SSc. Hiatal hernia, decreased esophageal contractility, and lower esophageal sphincter tone contribute to…
Abstract Number: 2039 • ACR Convergence 2025
To Hold or Not to Hold: Variability in Management of DMARDs in the Setting of Acute Infections – A Survey of Rheumatologists
Mollie Gellman¹, Medhasweta Sen², Ari Schwartz³, Peter Merkel⁴ and Nadine Mbuyi⁵, ¹Montefiore Medical Center, Bronx, NY, ²University of Virginia, Charlottesville, VA, ³Rheumatology Consultants PC, Brockton, MA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵George Washington University, Washington, DC
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) vary widely in their immunosuppressive activity. Guidance on managing DMARDs during acute infections is limited, particularly regarding when to hold…
Abstract Number: 0652 • ACR Convergence 2025
Evolution and Readiness: Preparing for Cell Therapy in Lupus Trials, A LuCIN Network Evaluation
Brandon Jackson¹, Saira Sheikh², Roberto Caricchio³, Taylor Irons⁴, Maria Dall'Era⁵, Amit Saxena⁶, Alfred Kim⁷, Jose Rubio⁸, Sasha Bernatsky⁹, David Goddard¹⁰, Fotios Koumpouras¹¹, Aimee Williams¹², Maya Merrell¹³, Jennifer Meriwether¹⁴ and Stacie Bell¹⁵, ¹Lupus Therapeutics, Miami, FL, ²University of North Carolina at Chapel Hill, Chapel Hill, NC, ³University of Massachusetts Chan Medical School, Worcester, MA, ⁴Lupus Therapeutics, Houston, TX, ⁵Division of Rheumatology, University of California, San Francisco, CA, ⁶NYU Grossman School of Medicine, New York, NY, ⁷Washington University School of Medicine, St. Louis, MO, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ¹⁰NYU Langone Grossman SOM, Brooklyn, NY, ¹¹Yale School of Medicine, New Haven, CT, ¹²Lupus Therapeutics, Raleigh, NC, ¹³Lupus Therapeutics, Charleston, SC, ¹⁴Lupus Therapeutics, Westminster, CO, ¹⁵Lupus Therapeutics, Lakewood, CO
Background/Purpose: Lupus Therapeutics (LT), the clinical affiliate of the Lupus Research Alliance, oversees the premier North American Lupus Clinical Investigators Network (LuCIN). As cell therapy…
Abstract Number: 2578 • ACR Convergence 2025
Association of Oral Outpatient Antiviral Medications for COVID-19 with the Risk of Post-Acute Sequelae of COVID-19 in Individuals with Systemic Autoimmune Rheumatic Diseases
Madison Negron¹, Jiaqi Wang², Xiaosong Wang³, Lauren O'Keeffe⁴, Grace Qian⁴, Kevin Mueller⁴, Alene Saavedra⁴, Natalie Davis⁵, Liya Sisay Getachew⁶, Jeffrey Sparks⁶ and Naomi Patel⁷, ¹Harvard Extension School, Medford, MA, ²Massachusetts General Hospital, BOston, ³Brigham and Women's Hospital, Natick, MA, ⁴Brigham and Women's Hospital, Boston, ⁵Brigham and Women's Hospital, Brookline, MA, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Massachusetts General Hospital, Boston, MA
Background/Purpose: Prior studies have evaluated the efficacy of antiviral medications on acute outcomes of COVID-19 infection as well as the risk of post-acute sequelae of…
Abstract Number: 2031 • ACR Convergence 2025
Management of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases: A Comparison of Rheumatologist and Pulmonologist Perspectives
Genna Braverman¹, Kerri Aronson², Charlene Thomas² and Robert Spiera³, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell, New York, NY, ³Scleroderma, Vasculitis, and Myositis Center, Hospital for Special Surgery, Weill Cornell Medical College, New York, NY
Background/Purpose: Interstitial lung disease (ILD) is common and important feature of systemic autoimmune rheumatic diseases (SARD). Rheumatologists and pulmonologists are central to the care of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].